Skip to main content

Clinical Use of Antibodies

Tumours, infection, infarction, rejection and in the diagnosis of AIDS

  • Book
  • © 1991

Overview

Part of the book series: Developments in Nuclear Medicine (DNUM, volume 19)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (14 chapters)

Keywords

About this book

It was at Frankfurt/Mainin 1899 that Paul Ehrlich first expounded his famous "site-chain theory" -which described the basic immunological principal of antibody-antigen interactio- on the occasion of the opening of the Institute for Experimental Therapeutics (which was later named after him). Nearly 100 years have passed since, and in retrospect it can be said that the "Ehrlich Era" (first steps in immunology "Magic Bullet" concept) and the "Behring Era" (detection of antibodies and serum therapy) formed the essential basis in the development of immunology. Niels K. Jerne, the former director of the Paul Ehrlich Institute in Frankfurt/Main received, together with Georges Kohler and Cesar Milstein, the Nobel Prize in Medicine 1984. These late successors of Ehrlich and Behring first described the hybridoma technology (in 1975) which enabled one of the most important and revolutionary technological innovations in the field of immunology -the production of monoclonal antibodies. It happens that, the time of the publication of this book, just a decade has passed since the first use of radiolabelled monoclonal antibodies in man (by the Lausanne Group). Over these 10 years a tremendous progress has taken place in the field of immunoscintigraphy:A large panel of highly specific monoclonal antibodies against tumour-associated antigens as well as normal cell compounds have been developed. Enormous progress has been made in the field of radiolabelling -from iodine-131 to technetium-99mor even positron-emittingradionuclides, e. g. iodine-124.

Reviews

'To conclude, this is a summary of research findings in Nuclear Medicine of predominant interest to Nuclear Medicine Physicians particularly those interested in "magic bullets", especially biological ones.' Australian Cancer Society 16:3 1992

Editors and Affiliations

  • Department of Nuclear Medicine, University Medical Center, Frankfurt, Germany

    Richard P. Baum, Gustav Hör

  • Department of Nuclear Medicine, Daniel den Hoed Clinic, Rotterdam, The Netherlands

    Peter H. Cox

  • Division of Nuclear Medicine, National Tumour Institute, Milan, Italy

    Gian Luigi Buraggi

Bibliographic Information

  • Book Title: Clinical Use of Antibodies

  • Book Subtitle: Tumours, infection, infarction, rejection and in the diagnosis of AIDS

  • Editors: Richard P. Baum, Peter H. Cox, Gustav Hör, Gian Luigi Buraggi

  • Series Title: Developments in Nuclear Medicine

  • DOI: https://doi.org/10.1007/978-94-011-3516-0

  • Publisher: Springer Dordrecht

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media Dordrecht 1991

  • Hardcover ISBN: 978-0-7923-1424-0Published: 31 October 1991

  • Softcover ISBN: 978-94-010-5555-0Published: 05 November 2012

  • eBook ISBN: 978-94-011-3516-0Published: 06 December 2012

  • Edition Number: 1

  • Number of Pages: X, 185

  • Topics: Nuclear Medicine, Diagnostic Radiology, Oncology

Publish with us